Novel medical therapies for gastroesophageal reflux disease beyond proton-pump inhibitors.
The control of TLESRs is a novel pharmacologic approach to the treatment of GERD. It is applicable in most reflux patients characterized as having nonerosive disease or patients with mild erosive disease. Currently, only the GABAB agonist baclofen is available for oral therapy, although side effects may be a limiting factor. Future drug development requires a better understanding of the central and peripheral mechanisms controlling TLESRs.
Richter
Joel E
JE
Departments of Gastroenterology/Hepatology, Cleveland Clinic Foundation, 9500 Euclid Avenue, A30, Cleveland, OH 44195, USA.
D001285:Atropine / Q000627:therapeutic use; D001418:Baclofen / Q000627:therapeutic use*; D003196:Computer Graphics; D004359:Drug Therapy, Combination; D018755:GABA Agonists / Q000627:therapeutic use*; D005764:Gastroesophageal Reflux / Q000188:drug therapy*; D006801:Humans; D010276:Parasympatholytics / Q000627:therapeutic use; D054328:Proton Pump Inhibitors; D016896:Treatment Outcome
D018755:GABA Agonists; D010276:Parasympatholytics; D054328:Proton Pump Inhibitors; D001285:Atropine; D001418:Baclofen